AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
zolmitriptan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| serotonin (5-HT1) receptor agonists, sumatriptan derivatives | 2869 | 139264-17-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an antimigraine compound; a serotonin (5HT)-1D receptor agonist
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2.50 | mg | N |
| 2.50 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.50 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 45 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.80 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.75 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.634 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.882 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.365 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.875 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 86.130 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 81.500 | % | High | 1 |
| herg | hERG pIC50 | 4.108 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.002 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.027 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 88.630 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIM2,PRKDC,SIK2,TEK | 23 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 2.042 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.622 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 4.742 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 84.120 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 4.093 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 90.360 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.015 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.119 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.930 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 86.620 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 944.061 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 25, 1997 | FDA | IPR |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Swollen tongue | 329.54 | 17.60 | 148 | 11997 | 45808 | 90570494 |
| Dysphonia | 299.38 | 17.60 | 153 | 11992 | 62931 | 90553371 |
| Angioedema | 292.45 | 17.60 | 152 | 11993 | 64724 | 90551578 |
| Drug ineffective for unapproved indication | 266.05 | 17.60 | 144 | 12001 | 66500 | 90549802 |
| Swelling face | 262.89 | 17.60 | 153 | 11992 | 81199 | 90535103 |
| Headache | 171.66 | 17.60 | 364 | 11781 | 862382 | 89753920 |
| Drug intolerance | 130.92 | 17.60 | 223 | 11922 | 447368 | 90168934 |
| Migraine | 122.69 | 17.60 | 139 | 12006 | 190253 | 90426049 |
| Vascular malformation | 107.47 | 17.60 | 24 | 12121 | 728 | 90615574 |
| Paranasal cyst | 105.70 | 17.60 | 24 | 12121 | 786 | 90615516 |
| Medication overuse headache | 105.52 | 17.60 | 27 | 12118 | 1474 | 90614828 |
| Mastoiditis | 102.66 | 17.60 | 27 | 12118 | 1643 | 90614659 |
| Skin candida | 64.85 | 17.60 | 19 | 12126 | 1722 | 90614580 |
| Hypersensitivity | 60.76 | 17.60 | 165 | 11980 | 454512 | 90161790 |
| Otitis media | 58.84 | 17.60 | 24 | 12121 | 5846 | 90610456 |
| Monocyte count abnormal | 51.93 | 17.60 | 11 | 12134 | 259 | 90616043 |
| Antibody test positive | 50.91 | 17.60 | 18 | 12127 | 2971 | 90613331 |
| Dyspnoea exertional | 46.84 | 17.60 | 53 | 12092 | 72235 | 90544067 |
| Urticaria chronic | 40.04 | 17.60 | 11 | 12134 | 790 | 90615512 |
| Lymphocyte count abnormal | 38.95 | 17.60 | 11 | 12134 | 874 | 90615428 |
| Infrequent bowel movements | 37.17 | 17.60 | 12 | 12133 | 1502 | 90614800 |
| Reversible cerebral vasoconstriction syndrome | 35.06 | 17.60 | 15 | 12130 | 4115 | 90612187 |
| Temperature intolerance | 34.53 | 17.60 | 21 | 12124 | 12009 | 90604293 |
| Off label use | 33.54 | 17.60 | 257 | 11888 | 1101995 | 89514307 |
| Vertigo | 33.53 | 17.60 | 44 | 12101 | 69767 | 90546535 |
| Congenital hypoplasia of depressor angularis oris muscle | 31.83 | 17.60 | 6 | 12139 | 76 | 90616226 |
| Disturbance in attention | 31.29 | 17.60 | 35 | 12110 | 47074 | 90569228 |
| Arthropathy | 30.55 | 17.60 | 6 | 12139 | 366236 | 90250066 |
| Nervous system disorder | 29.69 | 17.60 | 24 | 12121 | 21569 | 90594733 |
| Blood thyroid stimulating hormone normal | 29.40 | 17.60 | 6 | 12139 | 117 | 90616185 |
| Arteriospasm coronary | 29.10 | 17.60 | 14 | 12131 | 5036 | 90611266 |
| Colitis ischaemic | 29.05 | 17.60 | 19 | 12126 | 12327 | 90603975 |
| Stress | 28.32 | 17.60 | 44 | 12101 | 81351 | 90534951 |
| Blood immunoglobulin E increased | 27.74 | 17.60 | 13 | 12132 | 4412 | 90611890 |
| Polymenorrhagia | 27.52 | 17.60 | 5 | 12140 | 51 | 90616251 |
| General physical health deterioration | 27.24 | 17.60 | 7 | 12138 | 355108 | 90261194 |
| Oligohydramnios | 27.13 | 17.60 | 15 | 12130 | 7186 | 90609116 |
| Drug abuser | 26.97 | 17.60 | 11 | 12134 | 2679 | 90613623 |
| Myalgia | 26.83 | 17.60 | 67 | 12078 | 175058 | 90441244 |
| Tuberculosis | 26.36 | 17.60 | 18 | 12127 | 12531 | 90603771 |
| Stomatitis | 26.34 | 17.60 | 3 | 12142 | 274695 | 90341607 |
| Serotonin syndrome | 24.91 | 17.60 | 28 | 12117 | 37859 | 90578443 |
| Muscle discomfort | 24.06 | 17.60 | 6 | 12139 | 295 | 90616007 |
| Burns third degree | 23.77 | 17.60 | 6 | 12139 | 310 | 90615992 |
| Tuberculin test positive | 23.52 | 17.60 | 11 | 12134 | 3714 | 90612588 |
| Therapy partial responder | 23.16 | 17.60 | 21 | 12124 | 22022 | 90594280 |
| Thunderclap headache | 22.86 | 17.60 | 6 | 12139 | 362 | 90615940 |
| Aortic valve disease | 22.52 | 17.60 | 8 | 12137 | 1338 | 90614964 |
| Neutropenic sepsis | 22.52 | 17.60 | 19 | 12126 | 18111 | 90598191 |
| Oral herpes | 22.42 | 17.60 | 25 | 12120 | 33499 | 90582803 |
| Anaphylactic reaction | 22.08 | 17.60 | 41 | 12104 | 87483 | 90528819 |
| Depression | 21.93 | 17.60 | 89 | 12056 | 300512 | 90315790 |
| Blister | 21.63 | 17.60 | 4 | 12141 | 254994 | 90361308 |
| Paraesthesia ear | 21.57 | 17.60 | 6 | 12139 | 451 | 90615851 |
| Vitreous detachment | 21.39 | 17.60 | 9 | 12136 | 2369 | 90613933 |
| Systemic lupus erythematosus | 21.24 | 17.60 | 11 | 12134 | 361885 | 90254417 |
| Infusion related reaction | 21.20 | 17.60 | 15 | 12130 | 416765 | 90199537 |
| Hepatic enzyme increased | 21.12 | 17.60 | 11 | 12134 | 360725 | 90255577 |
| Tremor | 20.78 | 17.60 | 56 | 12089 | 153117 | 90463185 |
| Palpitations | 20.61 | 17.60 | 52 | 12093 | 136676 | 90479626 |
| Mouth ulceration | 20.45 | 17.60 | 26 | 12119 | 39948 | 90576354 |
| Product use in unapproved indication | 20.28 | 17.60 | 94 | 12051 | 336142 | 90280160 |
| Dizziness | 19.29 | 17.60 | 140 | 12005 | 589144 | 90027158 |
| Forced expiratory volume decreased | 18.92 | 17.60 | 11 | 12134 | 5797 | 90610505 |
| Constipation | 18.87 | 17.60 | 81 | 12064 | 280314 | 90335988 |
| Insomnia | 18.49 | 17.60 | 91 | 12054 | 333383 | 90282919 |
| Pneumonia | 18.47 | 17.60 | 36 | 12109 | 638023 | 89978279 |
| Dust allergy | 18.05 | 17.60 | 6 | 12139 | 823 | 90615479 |
| Broad ligament tear | 17.92 | 17.60 | 3 | 12142 | 18 | 90616284 |
| Cluster headache | 17.85 | 17.60 | 6 | 12139 | 851 | 90615451 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paraesthesia | 72.45 | 28.16 | 39 | 1360 | 73420 | 42546516 |
| Therapy partial responder | 66.84 | 28.16 | 25 | 1374 | 19996 | 42599940 |
| Drug abuse | 57.16 | 28.16 | 38 | 1361 | 104733 | 42515203 |
| Insomnia | 52.99 | 28.16 | 38 | 1361 | 118215 | 42501721 |
| Intentional product misuse | 37.47 | 28.16 | 24 | 1375 | 61876 | 42558060 |
| Craniosynostosis | 36.38 | 28.16 | 7 | 1392 | 429 | 42619507 |
| Medication overuse headache | 34.25 | 28.16 | 6 | 1393 | 218 | 42619718 |
| Migraine | 32.18 | 28.16 | 16 | 1383 | 25398 | 42594538 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Swollen tongue | 333.52 | 16.60 | 151 | 11581 | 60211 | 110517356 |
| Dysphonia | 309.37 | 16.60 | 154 | 11578 | 75775 | 110501792 |
| Swelling face | 286.53 | 16.60 | 156 | 11576 | 92165 | 110485402 |
| Angioedema | 274.36 | 16.60 | 155 | 11577 | 98345 | 110479222 |
| Drug ineffective for unapproved indication | 254.89 | 16.60 | 150 | 11582 | 102688 | 110474879 |
| Headache | 206.70 | 16.60 | 349 | 11383 | 882028 | 109695539 |
| Drug intolerance | 168.35 | 16.60 | 211 | 11521 | 406301 | 110171266 |
| Migraine | 130.64 | 16.60 | 123 | 11609 | 171529 | 110406038 |
| Medication overuse headache | 126.15 | 16.60 | 30 | 11702 | 1533 | 110576034 |
| Vascular malformation | 116.82 | 16.60 | 25 | 11707 | 789 | 110576778 |
| Paranasal cyst | 114.21 | 16.60 | 25 | 11707 | 879 | 110576688 |
| Mastoiditis | 101.56 | 16.60 | 28 | 11704 | 2583 | 110574984 |
| Hypersensitivity | 99.57 | 16.60 | 164 | 11568 | 403834 | 110173733 |
| Therapy partial responder | 68.70 | 16.60 | 45 | 11687 | 37016 | 110540551 |
| Otitis media | 62.09 | 16.60 | 25 | 11707 | 7451 | 110570116 |
| Skin candida | 59.46 | 16.60 | 18 | 11714 | 2310 | 110575257 |
| Insomnia | 44.66 | 16.60 | 110 | 11622 | 360480 | 110217087 |
| Off label use | 40.30 | 16.60 | 284 | 11448 | 1499901 | 109077666 |
| Disturbance in attention | 38.84 | 16.60 | 40 | 11692 | 61955 | 110515612 |
| Burns third degree | 37.39 | 16.60 | 9 | 11723 | 484 | 110577083 |
| Reversible cerebral vasoconstriction syndrome | 36.38 | 16.60 | 15 | 11717 | 4746 | 110572821 |
| Product use in unapproved indication | 30.94 | 16.60 | 111 | 11621 | 447266 | 110130301 |
| Blood thyroid stimulating hormone normal | 30.70 | 16.60 | 6 | 11726 | 119 | 110577448 |
| Renal infarct | 30.44 | 16.60 | 12 | 11720 | 3383 | 110574184 |
| Arteriospasm coronary | 29.90 | 16.60 | 16 | 11716 | 9084 | 110568483 |
| Polymenorrhagia | 28.77 | 16.60 | 5 | 11727 | 50 | 110577517 |
| Antibody test positive | 27.88 | 16.60 | 11 | 11721 | 3109 | 110574458 |
| Stress | 26.16 | 16.60 | 43 | 11689 | 105305 | 110472262 |
| Tuberculin test positive | 26.15 | 16.60 | 11 | 11721 | 3657 | 110573910 |
| Depression | 25.67 | 16.60 | 83 | 11649 | 317252 | 110260315 |
| Drug abuser | 25.06 | 16.60 | 12 | 11720 | 5397 | 110572170 |
| Drug abuse | 25.04 | 16.60 | 57 | 11675 | 177354 | 110400213 |
| Myalgia | 24.54 | 16.60 | 65 | 11667 | 222316 | 110355251 |
| Colitis ischaemic | 24.53 | 16.60 | 18 | 11714 | 17732 | 110559835 |
| Paraesthesia | 23.89 | 16.60 | 74 | 11658 | 276447 | 110301120 |
| Palpitations | 23.42 | 16.60 | 52 | 11680 | 159160 | 110418407 |
| Muscle discomfort | 22.74 | 16.60 | 6 | 11726 | 468 | 110577099 |
| Nervous system disorder | 22.69 | 16.60 | 22 | 11710 | 31699 | 110545868 |
| Vertigo | 22.30 | 16.60 | 36 | 11696 | 86834 | 110490733 |
| Paraesthesia ear | 22.02 | 16.60 | 6 | 11726 | 529 | 110577038 |
| Thunderclap headache | 21.56 | 16.60 | 6 | 11726 | 572 | 110576995 |
| Blood immunoglobulin E increased | 21.39 | 16.60 | 12 | 11720 | 7470 | 110570097 |
| Temperature intolerance | 21.23 | 16.60 | 15 | 11717 | 13935 | 110563632 |
| Tremor | 21.19 | 16.60 | 58 | 11674 | 202174 | 110375393 |
| Aortic valve disease | 20.42 | 16.60 | 8 | 11724 | 2219 | 110575348 |
| Pneumonia | 20.24 | 16.60 | 39 | 11693 | 876675 | 109700892 |
| Throat tightness | 19.88 | 16.60 | 21 | 11711 | 33468 | 110544099 |
| Febrile neutropenia | 19.11 | 16.60 | 5 | 11727 | 316762 | 110260805 |
| Vitreous detachment | 19.03 | 16.60 | 8 | 11724 | 2657 | 110574910 |
| Drug ineffective | 19.01 | 16.60 | 245 | 11487 | 1520295 | 109057272 |
| Stomatitis | 18.93 | 16.60 | 3 | 11729 | 270239 | 110307328 |
| Mouth ulceration | 18.26 | 16.60 | 24 | 11708 | 48114 | 110529453 |
| Trigemino-cardiac reflex | 18.08 | 16.60 | 5 | 11727 | 466 | 110577101 |
| Meningoencephalitis bacterial | 18.07 | 16.60 | 5 | 11727 | 467 | 110577100 |
| Bronchial obstruction | 17.92 | 16.60 | 8 | 11724 | 3071 | 110574496 |
| Nasal discharge discolouration | 17.62 | 16.60 | 8 | 11724 | 3193 | 110574374 |
| Nausea | 17.54 | 16.60 | 204 | 11528 | 1235486 | 109342081 |
| Major depression | 17.52 | 16.60 | 12 | 11720 | 10609 | 110566958 |
| Stress cardiomyopathy | 17.39 | 16.60 | 14 | 11718 | 15792 | 110561775 |
| Cluster headache | 17.21 | 16.60 | 6 | 11726 | 1201 | 110576366 |
| Monoplegia | 17.17 | 16.60 | 9 | 11723 | 4900 | 110572667 |
| Mitral valve disease | 17.10 | 16.60 | 8 | 11724 | 3417 | 110574150 |
| Sacroiliitis | 17.05 | 16.60 | 9 | 11723 | 4969 | 110572598 |
| Coronary artery dissection | 17.02 | 16.60 | 6 | 11726 | 1242 | 110576325 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N02CC03 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Selective serotonin (5HT1) agonists |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D058825 | Serotonin 5-HT1 Receptor Agonists |
| FDA MoA | N0000175763 | Serotonin 1b Receptor Agonists |
| FDA MoA | N0000175764 | Serotonin 1d Receptor Agonists |
| FDA EPC | N0000175765 | Serotonin-1b and Serotonin-1d Receptor Agonist |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
Related Drugs by ATC class:
N02CC Selective serotonin (5HT1) agonists 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Migraine | indication | 37796009 | DOID:6364 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hemiplegic migraine | contraindication | 59292006 | |
| Cerebral arteriosclerosis | contraindication | 65312002 | |
| Wolff-Parkinson-White pattern | contraindication | 74390002 | DOID:384 |
| Vascular insufficiency of intestine | contraindication | 82196007 | |
| Prinzmetal angina | contraindication | 87343002 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Angina pectoris | contraindication | 194828000 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Transient ischemic attack | contraindication | 266257000 | DOID:224 |
| Raynaud's phenomenon | contraindication | 266261006 | |
| Cerebral ischemia | contraindication | 287731003 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Peripheral vascular disease | contraindication | 400047006 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.47 | acidic |
| pKa2 | 8.28 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1D | GPCR | AGONIST | Ki | 8.90 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 1B | GPCR | AGONIST | Ki | 7.70 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 1E | GPCR | Ki | 7.70 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.60 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1F | GPCR | Ki | 7.45 | WOMBAT-PK | |||||
| D(2) dopamine receptor | GPCR | Kd | 10.40 | CHEMBL | |||||
| D(1A) dopamine receptor | GPCR | Kd | 9.52 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Kd | 8.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021094 | VUID |
| N0000148550 | NUI |
| D00415 | KEGG_DRUG |
| 4021094 | VANDF |
| C0528166 | UMLSCUI |
| CHEBI:10124 | CHEBI |
| CHEMBL1185 | ChEMBL_ID |
| DB00315 | DRUGBANK_ID |
| C089750 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60857 | PUBCHEM_CID |
| 60 | IUPHAR_LIGAND_ID |
| 7408 | INN_ID |
| 2FS66TH3YW | UNII |
| 135775 | RXNORM |
| 52759 | MMSL |
| 5712 | MMSL |
| d04253 | MMSL |
| 006460 | NDDF |
| 108406003 | SNOMEDCT_US |
| 363582006 | SNOMEDCT_US |
| 2FS66TH3YW | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zolmitriptan | Human Prescription Drug Label | 1 | 16571-803 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 16571-804 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-955 | SPRAY, METERED | 5 mg | NASAL | NDA | 28 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 27241-021 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 27241-022 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
| Zolmitriptan OD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-998 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan OD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-999 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 25 sections |
| zolmitriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-711 | SPRAY | 5 mg | NASAL | ANDA | 26 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 46708-181 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 46708-182 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 46708-462 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 46708-463 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan OD | Human Prescription Drug Label | 1 | 59746-461 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 26 sections |
| Zolmitriptan OD | Human Prescription Drug Label | 1 | 59746-461 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 26 sections |
| Zolmitriptan OD | Human Prescription Drug Label | 1 | 59746-462 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
| Zolmitriptan OD | Human Prescription Drug Label | 1 | 59746-462 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 26 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60846-130 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 26 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60846-133 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60846-2383 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 26 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60846-2384 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 62332-181 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 62332-182 | TABLET, ORALLY DISINTEGRATING | 5 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 62332-462 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | Human Prescription Drug Label | 1 | 62332-463 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63548-0101 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 25 sections |
| Zolmitriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63548-0102 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 25 sections |
| zolmitriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-9575 | SPRAY | 5 mg | NASAL | ANDA | 26 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64896-083 | SPRAY, METERED | 2.50 mg | NASAL | NDA | 27 sections |
| ZOMIG | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64896-084 | SPRAY, METERED | 5 mg | NASAL | NDA | 27 sections |
| Zolmitriptan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65841-767 | TABLET, ORALLY DISINTEGRATING | 2.50 mg | ORAL | ANDA | 1 sections |